The European Medicines
Agency’s Pharmacovigilance Risk
Assessment Committee (PRAC)
has recommended that Protelos/
Osseor should no longer be used to
treat osteoporosis.
The recommendation follows an
in-depth review of the risks and
benefits of the medication showing
that for every 1,000 patient-years
there were 4 more cases of serious
heart problems and 4 more cases
of blood clots or blockages of blood
vessels with Protelos/Osseor than
with placebo.
To see other complications and
further details, CLICK HERE.The above article was sent to subscribers in Pharmacy Daily's issue from 13 Jan 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 13 Jan 14
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
AUSTRALIA’S public hospitals are facing their lengthiest wait times on record for planned surgeries, with emergency departments struggling under access blockages, according to the latest annual Public Hospital Report Card by the Australian Medical Association (AMA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.